NVCR

NovoCure Limited Healthcare - Medical Devices Investor Relations →

YES
71.6% BELOW
↓ Approaching Was -65.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $35.72
14-Week RSI 39

NovoCure Limited (NVCR) closed at $10.14 as of 2026-02-02, trading 71.6% below its 200-week moving average of $35.72. This places NVCR in the extreme value zone. The stock is currently moving closer to the line, down from -65.7% last week. The 14-week RSI sits at 39, indicating neutral momentum.

Over the past 492 weeks of data, NVCR has crossed below its 200-week moving average 2 times. On average, these episodes lasted 128 weeks. Historically, investors who bought NVCR at the start of these episodes saw an average one-year return of +153.4%.

With a market cap of $1135 million, NVCR is a small-cap stock. The company generates a free cash flow yield of 2.2%. Return on equity stands at -50.6%. The stock trades at 3.3x book value.

Share count has increased 4.4% over three years, indicating dilution.

Over the past 9.5 years, a hypothetical investment of $100 in NVCR would have grown to $119, compared to $373 for the S&P 500. NVCR has returned 1.8% annualized vs 14.9% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $1,228,659. Notably, these purchases occurred while NVCR is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: NVCR vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After NVCR Crosses Below the Line?

Across 2 historical episodes, buying NVCR when it crossed below its 200-week moving average produced an average return of +65.0% after 12 months (median +132.0%), compared to +5.0% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +214.5% vs +21.5% for the index.

Each line shows $100 invested at the moment NVCR crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-09-05CORDOVA ASHLEYChief Executive Officer$996,85981,550+22.9%

Historical Touches

NVCR has crossed below its 200-week MA 2 times with an average 1-year return of +153.4% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Sep 2016May 20173757.5%+153.4%+25.3%
Nov 2021Ongoing219+88.1%Ongoing-87.6%
Average128+153.4%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02